HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager patientINFORMation Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Xiang, A. H. Articles by Buchanan, T. A. Search for Related Content PubMed PubMed Citation Articles by Xiang, A. H. Articles by Buchanan, T. A. Social Bookmarking                What's this?

Long-Acting Injectable Progestin Contraception and Risk of Type 2 Diabetes in Latino Women With Prior Gestational Diabetes Mellitus

¹ Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, California
² Department of Obstetrics and Gynecology, University of Southern California Keck School of Medicine, Los Angeles, California
³ Department of Obstetrics and Gynecology, Harbor UCLA Medical Center, Torrance, California
⁴ Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, California

Address correspondence reprint requests to Anny H. Xiang, PhD, Keck School of Medicine, University of Southern California, Department of Preventive Medicine, 1540 Alcazar St., CHP-222, Los Angeles, CA 90033. E-mail: xiang{at}usc.edu

OBJECTIVE—To investigate the impact of a long-acting injectable progestin, depo-medroxyprogesterone acetate (DMPA), compared with combination oral contraceptives (COCs) on the risk of diabetes in Latino women with prior gestational diabetes mellitus (GDM).

RESEARCH DESIGN AND METHODS—An observational cohort study of 526 Hispanic women with prior GDM who were not diabetic in their postpartum visit during January 1987 to October 1997 and who elected DMPA (n = 96) or COCs (n = 430) as initial contraception were followed for a maximum of 9.2 years with a median follow-up of 12 months. Oral glucose tolerance tests were performed and choice of contraception method was recorded at each visit as part of routine clinical care.

RESULTS—Annual diabetes incidence rates were 19% in the DMPA group and 12% in the COC group, with an unadjusted hazard ratio (HR) of 1.58 (95% CI 1.00–2.50; P = 0.05) for DMPA compared with COCs. Adjustment for baseline imbalances reduced the HR to 1.18 (0.67–2.28; P = 0.57). Additional adjustment for weight gain during follow-up, which was on average 1.8 kg higher in the DMPA group (P < 0.0001), reduced the HR to 1.07. DMPA interacted with baseline serum triglyceride levels and, separately, with breast-feeding to increase the diabetes risk.

CONCLUSIONS—DMPA use was associated with an increased risk of diabetes that appeared to be explained by three factors: 1) use in women with increased baseline diabetes risk, 2) weight gain during use, and 3) use with high baseline triglycerides and/or during breast-feeding.

Abbreviations: COC, combination oral contraceptive • DMPA, depo-medroxyprogesterone acetate • GDM, gestational diabetes mellitus • OGTT, oral glucose tolerance test

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

Find additional patient-related information at:

Birth Control Injections May Increase Risk for Type 2 in Women Who Have Had Gestational Diabetes

This article has been cited by other articles:

				A. H. Xiang, M. Kawakubo, T. A. Buchanan, and S. L. Kjos A Longitudinal Study of Lipids and Blood Pressure in Relation to Method of Contraception in Latino Women With Prior Gestational Diabetes Mellitus Diabetes Care, August 1, 2007; 30(8): 1952 - 1958. [Abstract] [Full Text] [PDF]

				P. Damm, E. R. Mathiesen, K. R. Petersen, and S. Kjos Contraception After Gestational Diabetes Diabetes Care, July 1, 2007; 30(Supplement_2): S236 - S241. [Full Text] [PDF]